Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Citations
1,179 citations
672 citations
499 citations
473 citations
458 citations
References
5,004 citations
3,207 citations
"Twenty-four-Month Efficacy and Safe..." refers result in this paper
...The HARBOR PRN groups also had similar results to visual outcomes observed in the fixed monthly dose trials in MARINA(8) and ANCHOR.(6,7) By looking at the evaluation intervals of the 4 clinical trials with less-than-monthly ranibizumab dosing groups (HARBOR, CATT, PIER and SAILOR; Fig 4), it is evident that the durability of effect with ranibizumab can be extended in many patients using a closely monitored PRN regimen that incorporates prompt recognition of recurrent OCT activity or decrease in VA in contrast to loss of VA gains in a quarterly fixed-dose regimen....
[...]
...The HARBOR PRN groups also had similar results to visual outcomes observed in the fixed monthly dose trials in MARINA8 and ANCHOR.6,7 By looking at the evaluation intervals of the 4 clinical trials with less-than-monthly ranibizumab dosing groups (HARBOR, CATT, PIER and SAILOR; Fig 4), it is evident that the durability of effect with ranibizumab can be extended in many patients using a closely monitored PRN regimen that incorporates prompt recognition of recurrent OCT activity or decrease in VA in contrast to loss of VA gains in a quarterly fixed-dose regimen....
[...]
2,425 citations
2,389 citations
1,894 citations